FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ľ	4		

0

D

OMB APPROVAL 3235-0287

OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Common Stock

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

See Instruction	on 10.	,-											
1. Name and Address of Reporting Person* Zoth Lota S.				2. Issuer Name and Ticker or Trading Symbol LUMOS PHARMA, INC. [(LUMO)]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Universely Director 10% Owner				
(Last) 4200 MARA SUITE 200	(First) THON BLVD.	(Middle)	1	12/12/							Officer (give title below)	below	
			4	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. Indi	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) AUSTIN	TX	78756									Form filed by On Form filed by Mo Person		
(City)	(State)	(Zip)											
		Table I - No	n-Derivati	ive Se	ecurities Acqu	ıired,	Disp	osed of, o	r Ben	eficially	Owned		
		Date	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D)	Price	Transaction(s)		(

D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

2,187

D

12/12/2024

(e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and Expiration Date (Month/Day/Year) 10. Ownership Form: 1. Title of 3. Transaction 3A. Deemed Execution Date 5. Number 7. Title and 8. Price of Derivative 9. Number of 11. Nature of Indirect Transaction Code (Instr. Conversion Derivative Amount of Securities derivative (Month/Day/Year) Derivative if any Security or Exercise Security Securities Beneficial Beneficially Owned Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) 8) Securities (Instr. 5) Direct (D) Acquired (A) or or Indirect (I) (Instr. 4) Security (Instr. 3 and 4) Following Disposed of (D) (Instr. 3, 4 Reported Transaction(s) (Instr. 4) and 5) Amount Number Expiration Date Date Exercisable of Shares ν (A) (D) Title Code Stock Option 12/12/2024 D (2) 3.345 (2) 3,345 05/09/2033 0 D (Right to Stock Buy) Stock Option Commor (2) 06/04/2034 (2) \$2.35 12/12/2024 D 3 328 3 328 0 D (Right to Buy) Stock Option 12/12/2024 D (3) 04/02/2030 5,684 (3) D (Right to Stock Buy) Stock Option Commor (3) 05/04/2032 (3) 12/12/2024 D 3 431 0 D \$8 18 3,431 (Right to Stock Buy) Stock Option 12/12/2024 D (3) 05/19/2031 2,910 (3) 0 D (Right to Stock Buy) Stock Option Commor 12/12/2024 D (3) 05/09/2029 (3) \$15.21 0 D 2.777 2.777 (Right to Stock Buy) Stock Option \$15.93 12/12/2024 D (3) (3) 5.324 07/31/2026 5,324 D (Right to Stock Buy)

Explanation of Responses:

- 1. Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (ii) \$4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
- 2. This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.
- 3. Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement.

Remarks:

/s/ Ryan Trytten, attorney-in- 12/13/2024 fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.